Aeon Biopharma Inc (AEON) Stock Price, Quote & News

Company Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceu...

Industry: Biotechnology

Sector: Healthcare

Phone: 949 354 6499

Website: www.aeonbiopharma.com

Address:

5 Park Plaza, Suite 1750, Irvine, United States

TWITLIEDETECTOR Mar. 16 at 5:01 AM

$AEON Posted too much here. you are a boring group. will hold my position but i am moving on to observe some other stocks more closely. i never buy in too fast i study and watch.

1 · Reply

TWITLIEDETECTOR Mar. 14 at 10:45 PM

$AEON consolidation has completely changed resistance. i am no stock expert but this play has changed.

1 · Reply

VinWeezel Mar. 13 at 7:52 PM

$AEON free dorito alerts. Rob Bancroft apparently loves cooler ranch and had a meeting about a new flavor he won’t tell us about.

0 · Reply

Mandi63 Mar. 13 at 6:19 PM

$AEON one a-hole keeps bring this stock down.. please stop..use your skills to move it up..

1 · Reply

Mandi63 Mar. 13 at 2:43 PM

$AEON waiting…i sold a stock years ago for 1.00 something …it layer hit $200…lol would have been a millionaire a few times … management matters..

1 · Reply

TWITLIEDETECTOR Mar. 13 at 4:01 AM

$AEON some of you said there was no dd left to do. perhaps now that is true

0 · Reply

TWITLIEDETECTOR Mar. 11 at 5:51 PM

$AEON 1.09 to the rescue. told you so LOL

1 · Reply

TWITLIEDETECTOR Mar. 11 at 5:09 PM

$AEON has to break 1.22

0 · Reply

VinWeezel Mar. 11 at 4:28 PM

$AEON visions of 1.80.

0 · Reply

TWITLIEDETECTOR Mar. 11 at 2:58 AM

$AEON $1.09 is back. remember why?

2 · Reply

AEON Biopharma Reports BPD Type 2a Meeting with FDA and Shareholder Approval of the November Transactions

Dec 19, 2025, 6:00 PM EST - 3 months ago

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

Dec 15, 2025, 4:05 PM EST - 3 months ago

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

Nov 20, 2025, 8:30 AM EST - 4 months ago

AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling

Nov 14, 2025, 8:30 AM EST - 4 months ago

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

Nov 13, 2025, 8:30 AM EST - 4 months ago

AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes

Oct 1, 2025, 8:00 AM EDT - 5 months ago

AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19

Aug 12, 2025, 4:05 PM EDT - 7 months ago

AEON Biopharma Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 19, 2025, 4:05 PM EDT - 10 months ago

AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025

May 14, 2025, 4:05 PM EDT - 10 months ago

AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 25, 2025, 4:05 PM EDT - 11 months ago

AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Apr 21, 2025, 4:05 PM EDT - 11 months ago

AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

Mar 27, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Announces CEO Transition

Mar 24, 2025, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 4, 2025, 8:00 AM EST - 1 year ago

AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference

Feb 24, 2025, 2:00 PM EST - 1 year ago

AEON Biopharma, Inc. Announces Reverse Stock Split

Feb 7, 2025, 4:05 PM EST - 1 year ago

AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Jan 7, 2025, 9:37 AM EST - 1 year ago

AEON Biopharma, Inc. Announces Closing of $20.0 Million Underwritten Public Offering

Jan 3, 2025, 8:02 PM EST - 1 year ago

AEON Biopharma, Inc. Announces Launch of Proposed Public Offering

Nov 13, 2024, 4:05 PM EST - 1 year ago

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Aug 19, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 12, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

May 29, 2024, 8:00 AM EDT - 1 year ago

AEON Biopharma Announces Strategic Resource Reprioritization and Cost Reduction Plan

May 14, 2024, 4:05 PM EDT - 1 year ago

AEON Biopharma Reports First Quarter 2024 Financial Results

May 9, 2024, 8:00 AM EDT - 2 years ago

AEON Biopharma Provides Update on Development Pipeline

May 3, 2024, 7:00 AM EDT - 2 years ago

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

Mar 30, 2024, 10:53 PM EDT - 2 years ago

CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 4:15 PM EDT - 2 years ago

AEON Biopharma Announces Redemption of Public Warrants

Mar 29, 2024, 3:45 PM EDT - 2 years ago

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 19, 2024, 4:30 PM EDT - 2 years ago

AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine

Mar 19, 2024, 4:29 PM EDT - 2 years ago

AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements

Jan 18, 2024, 4:05 PM EST - 2 years ago

AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference

Dec 12, 2023, 8:00 AM EST - 2 years ago

AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine

Nov 13, 2023, 8:15 AM EST - 2 years ago

AEON Biopharma Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 4:05 PM EDT - 2 years ago

AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

Aug 29, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®

Aug 24, 2023, 8:00 AM EDT - 2 years ago

AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

Jul 24, 2023, 7:00 AM EDT - 2 years ago

AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

TWITLIEDETECTOR Mar. 16 at 5:01 AM

$AEON Posted too much here. you are a boring group. will hold my position but i am moving on to observe some other stocks more closely. i never buy in too fast i study and watch.

1 · Reply

TWITLIEDETECTOR Mar. 14 at 10:45 PM

$AEON consolidation has completely changed resistance. i am no stock expert but this play has changed.

1 · Reply

VinWeezel Mar. 13 at 7:52 PM

$AEON free dorito alerts. Rob Bancroft apparently loves cooler ranch and had a meeting about a new flavor he won’t tell us about.

0 · Reply

Mandi63 Mar. 13 at 6:19 PM

$AEON one a-hole keeps bring this stock down.. please stop..use your skills to move it up..

1 · Reply

Mandi63 Mar. 13 at 2:43 PM

$AEON waiting…i sold a stock years ago for 1.00 something …it layer hit $200…lol would have been a millionaire a few times … management matters..

1 · Reply

TWITLIEDETECTOR Mar. 13 at 4:01 AM

$AEON some of you said there was no dd left to do. perhaps now that is true

0 · Reply

TWITLIEDETECTOR Mar. 11 at 5:51 PM

$AEON 1.09 to the rescue. told you so LOL

1 · Reply

TWITLIEDETECTOR Mar. 11 at 5:09 PM

$AEON has to break 1.22

0 · Reply

VinWeezel Mar. 11 at 4:28 PM

$AEON visions of 1.80.

0 · Reply

TWITLIEDETECTOR Mar. 11 at 2:58 AM

$AEON $1.09 is back. remember why?

2 · Reply

BryceyBoy Mar. 10 at 2:33 PM

$AEON Would be interesting if they released the approval right before they do their presentation.

1 · Reply

TWITLIEDETECTOR Mar. 10 at 12:55 AM

$AEON this is a boring board.

2 · Reply

TWITLIEDETECTOR Mar. 9 at 11:52 PM

$AEON the filing has more details. this seems pretty promising now

0 · Reply

TWITLIEDETECTOR Mar. 9 at 9:21 PM

$AEON new CFO at aeon.

0 · Reply

TWITLIEDETECTOR Mar. 8 at 10:54 PM

$AEON EOLS had a good week. read up on daewoong. they are doing quite well

0 · Reply

kwongaram Mar. 8 at 4:36 PM

$AEON 100%

1 · Reply

Revempire Mar. 8 at 5:48 AM

$AEON the company announced that an abstract for its lead candidate, ABP-450, was accepted for presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting.

0 · Reply

TWITLIEDETECTOR Mar. 7 at 11:14 PM

$AEON after a lot more reading. i am 75 percent convinced we will make some money.

0 · Reply

RaiderNation5413 Mar. 6 at 12:17 PM

$AEON moving north today...but how much?

1 · Reply

TWITLIEDETECTOR Mar. 6 at 6:23 AM

$AEON read up on the AAN. i was surprised in a happy way

0 · Reply

TWITLIEDETECTOR Mar. 6 at 5:04 AM

$AEON one lesson i promise you is true. all baby bios are liars and it’s your job to figure out how much you’re being lied to.

0 · Reply

TWITLIEDETECTOR Mar. 5 at 11:53 PM

$AEON i just found another filing today. please check my work to see if these look good

2 · Reply

Market Cap	13.14M
Revenue (ttm)	0.00
Net Income (ttm)	42.01M
EPS (ttm)	N/A
PE Ratio	0.42
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	69,600
Avg Vol	172,184
Day's Range	N/A - N/A
Shares Out	11.84M
Stochastic %K	51%
Beta	0.72
Analysts	Strong Sell
Price Target	$6.10